AbbVie's atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA

Retrieved on: 2021-04-01 15:11:15

Tags for this article:

Click the tags to see associated articles and topics

AbbVie's atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA. View article details on hiswai:

Excerpt

Atogepant is set to compete with CGRP monoclonal antibodies (mAbs), Amgen's erenumab, Eli Lilly's galcanezumab, Teva's fremanezumab, and ...

Article found on: www.clinicaltrialsarena.com